Chuang-Wei Wang

Title: Chuang-Wei Wang and a Patent for Assessing Antiepileptic Drug Hypersensitivity Risk.

Introduction

Chuang-Wei Wang is an inventor based in Taoyuan, Taiwan, associated with Chang Gung Memorial Hospital, Linkou. His patent work addresses the assessment and management of hypersensitivity reactions to certain antiepileptic drugs.

Latest Patents

Wang is associated with 1 patent: “Method and Kit for Testing Drug Hypersensitivity Reactions Caused by Sulfonamide Derivative-Based Antiepileptic Drug and Use of the Kit.” The invention describes testing a patient’s sample for specific HLA-B alleles to assess whether the patient may have an increased risk of a hypersensitivity reaction to an antiepileptic drug containing a sulfonamide derivative. It also describes approaches to treating or reducing the incidence of such reactions, along with a test kit containing reagents for identifying the relevant HLA alleles.

Career Highlights

Wang’s patent reflects work at the intersection of genetic testing and medication safety. By using HLA allele detection to inform risk assessment, the invention aims to support clinical decisions about treatment with sulfonamide derivative-based antiepileptic drugs.

Collaborations

Wen-Hung Chung and Shuen-Iu Hung are identified as Wang’s coworkers. His institutional association is Chang Gung Memorial Hospital, Linkou.

Conclusion

Chuang-Wei Wang’s patent focuses on using HLA-B allele testing to assess and help manage the risk of drug hypersensitivity reactions, contributing to research on safer antiepileptic drug use.